Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine

Dynela Garcia-Baran, MD, LCDR, MC, USN, Thomas M. Johnson, MD, CAPT, Joyce Wagner, PA-C, Joann Shen, MS, LCDR, USPS, and Michelle Geers, MS, DVBIC

INTRODUCTION

Pathological laughing and crying, or pseudobulbar affect (PBA), has been described in patients with neurological disorders such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease, stroke, and traumatic brain injury (TBI) since the 19th century. The syndrome is characterized by inappropriate episodes of laughing or crying after minor stimuli. It was first coined a disinhibition of cortical control by Kinnier Wilson. It was observed in brain disease and seen crying after minor stimuli. It was first coined a disinhibition of cortical syndrome is characterized by inappropriate episodes of laughing or crying after minor stimuli that would not typically cause such an outburst and are embarrassing to him. His past medical history was remarkable for the diagnosis of posttraumatic stress disorder (PTSD) which started after the assault, as well as various orthopedic injuries, including an ankle injury. He was taking prazosin 2 mg qhs, nortriptyline 50 mg qhs, and eszopiclone 2 mg qhs when he presented to the clinic. He had no known drug allergies.

Physical examination was remarkable only for antalgic gait due to an orthopedic injury to his ankle. His neurological examination was remarkable for the Center for Neurologic Study-Lability Scale (CNS-LS) for PBA of 26, where CNS-LS of 13 or higher is highly suggestive of PBA (Figure 1). His funduscopic examination, cranial nerve, motor, sensory, and cerebellar examination were all normal. He had some difficulty with Romberg testing and gait because of his ankle injury. This
reflexes were 2/4, and Babinski testing demonstrated down-going toes. Laboratory testing was unremarkable, and EKG was normal. Magnetic resonance imaging of the brain revealed an area of increased signal in the right frontal lobe. However, these lesions had described previously as age appropriate. They have also been seen and described in PBA (Figure 2).

He started taking 20 mg DM/10 mg Q, 1 tablet a day. He felt better after taking this medication for several weeks so he discontinued the medication on his own accord, but then the symptoms of PBA returned. He again started taking 20 mg DM/10 mg Q and was titrated up to twice a day dosing. He is currently on this dose of the medication, and reports that he is

FIGURE 1. CNS-LS for PBA. CNS-LS = Center for Neurologic Study-Lability Scale, PBA = pseudobulbar affect.
able to “shut the door” again and control his emotional volatility when taking the medication, and that the symptoms of PBA have resolved. He reported no side effects or problems with taking the medication.

**DISCUSSION**

The regulation of mood and affect is a complicated and poorly understood phenomenon. It probably involves at the very least emotional input from the limbic system that is projected to the frontal cortex; projections from the frontal cortex via the corticobulbar tracts to the cranial nerves in the brainstem results in facial nerve activation manifesting as laughing or crying, with additional input from the cerebellum modulating motor activity.

The exact neuroanatomy involved in the regulation of mood and affect is unclear, but there is a consensus in the literature that it involves several areas of the brain functioning as a neural network with multiple feedback loops regulating cortical activity. Such a network would be vulnerable to countercoup injury, as well as axonal shear injuries, which is commonly seen in TBI.

The neuropharmacology of all the receptors and neurotransmitters involved in the regulation of mood and affect is probably even less understood than the neuroanatomy. However, there is evidence that tonic activation of the N-methyl-D-aspartate glutamate (NMDA) receptor can cause neuronal injury and death. Phasic activation of the receptor can cause learning difficulties and learning impairment.

DM is a known low affinity noncompetitive antagonist of the NMDA receptors. It is also a sigma receptor agonist, and has been shown to have a neuroprotective effect on injured brain. Q is a potent cytochrome P450 2D6 inhibitor, and slows the metabolism of DM, resulting in higher levels of DM for longer periods in the bloodstream; 20 mg of DM and 10 mg of Q were married to create DM/Q (Nuedexta).

The most common side effect of DM/Q is dizziness, nausea, and headaches. The most concerning side effect is from Q, which has been used to treat atrial fibrillation and flutter, but can cause prolonged QT syndrome in the 1000 mg/d dosage range. However, the dose of Q in DM/Q is approximately 100 times less than the order of magnitude typically associated with cardiac side effects.

Based on this pharmacological information, DM/Q was evaluated and found in 3 different double blind, randomized clinical studies to significantly improve the symptoms of PBA in people suffering from MS or ALS. There is a paucity of data about the use of DM/Q in TBI, especially in high functioning individuals with TBI such as the individual described in this case report.1,4,5

**CONCLUSION**

This Marine had a TBI with complete amnesia of events surrounding and including the assault that caused the TBI. He then presented with classic symptoms seen after a TBI, including headaches, problems with mood, memory, and sleep. He also gave a remarkably insightful description of intrusive thoughts and memories that he could longer “close the door” on and control that is consistent with his diagnosis of PTSD.

Such scenarios, where an individual does not consciously recall a trauma that they have experienced and then go on to develop PTSD, are not uncommon, and may be due to the individual striving to cope with the repercussions of the trauma. This individual had an improvement in not just his PBA, but also ability to manage intrusive memories, when taking DM/Q. This suggests that individuals who have developed PBA as a result of TBI could potentially benefit from DM/Q. It also raises the possibility that there is a neuroanatomical and/or neurophysiological disorder that manifests itself clinically as PTSD that responds to DM/Q.

There is no evidence that this individual experienced any adverse effects or harm from taking DM/Q. He was being treated with several medications and receiving cognitive, occupational, vestibular, and other therapies at the same time he was treated with DM/Q, so it is not possible to attribute his clinical improvement solely to the DM/Q. However, the fact that he discontinued the medication and then had a worsening of symptoms, and then restarted the medication with improvement of symptoms, suggests that he was benefiting from the DM/Q. Further studies are required to determine if DM/Q is effective in the treatment of PBA in TBI patients.

**REFERENCES**

1. Pioro EP, Brooks BR, Cummings J, et al. Safety, Tolerability, and Efficacy Results Trial of AYP-923 in PBS Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. *Ann Neurol.* 2010;68:693–702.

2. Parsons CG, Stoffler A, Danyss W. Mementine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. *Neuropsychopharmacology.* 2007;53:699–723.

3. Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. *Neurologist.* 2007;13:272–293.

4. Brooks BR, Thisted RA, Appel SH, et al., AYP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. *Neurology.* 2004;63:1364–1370.

5. Panitch HS, Thisted RA, Smith RA, et al., Pseudobulbar Affect in Multiple Sclerosis Study Group. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. *Ann Neurol.* 2006;59:780–787.

6. Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. *J Neuropsychiatry Clin Neurosci.* 2005;17:447–454.

7. Wilson SA. Original papers: some problems in neurology. *J Neurol Psychopath.* 1924;4:299–333.